https://www.selleckchem.com/pr....oducts/pemigatinib-i
Though the current gold standard for diagnosing thyroid nodule malignancy is ultrasound-guided fine-needle aspiration (USFNA) cytology, about 20-25% of cytological evaluations are considered indeterminate for malignancy. This limitation has led to the emergence of next-generation sequencing panels, e.g. ThyroSeq v3 (TSv3), which recognize highly-diagnostic genetic mutations of common thyroid carcinomas in FNA samples and classifies them as test-negative or test-positive, helping optimize treatment for indeterminate thyroi
Like
Comment
Share
